Key Drivers
- Strong liquidity
- Very high valuation
- One‑time gains
AIAI Summary
SLNO has effectively become a cash-generating specialty‑pharma whose valuation now rests on commercial execution — specifically whether payer coverage, PSF→active→repeat fill conversion and normalized COGS sustain unit economics — so investors should watch sequential revenue beats, discontinuation rates, and litigation/regulatory outcomes as the decisive value drivers.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Very high valuation
- •One‑time gains
SLNO has strong liquidity, positive free cash flow and low leverage but appears richly valued and reliant on one‑time gains rather than sustainable operating returns.
Price Behavior
Key Price Behavior Insights:
- •Recent downtrend
- •Low‑33 tests
- •Resistance near $40
SLNO is in a clear downtrend over the last month (~19% drop to low‑33), testing a low‑33 support band that could either produce a bounce or break decisively with sustained selling, while a move above ~$40 would be needed to confirm any trend reversal.
Volatile swing from mid‑$40s in
Sentiment & News
Key News Insights:
- •Multiple law firms
- •Lead‑plaintiff deadline
- •Avoro stake increase
Soleno (SLNO) faces concentrated securities‑litigation notices from multiple firms (class period largely Mar–Nov 2025; lead‑plaintiff deadline 2026‑05‑05) alongside a notable mid‑March institutional stake increase, signaling heightened legal risk despite investor interest.
Elevated litigation exposure is likely to increase volatility and legal overhang risk for SLNO in the near term, even as institutional buying could provide some support
Similar Companies in Healthcare
Other companies in the same sector with AI ratings